Spectrum jumps after FDA completes inspection of neutropenia drug plant
11/08/2022 16:06
** Shares of Spectrum Pharmaceuticals Inc SPPI.O rise
10.7% to $1.24, a four-month high
** Co says FDA completes re-inspection of a manufacturing
facility for its experimental therapy for treating neutropenia,
or low levels of a type of white blood cell called neutrophils
urn:newsml:reuters.com:*:nBw7h1BQJa
** FDA in June initiated the pre-inspection of a South
Korean manufacturing plant after a delay due to COVID-19
restrictions urn:newsml:reuters.com:*:nBwbN0JH6a
** Including session's gain, stock down 2.3% YTD, compared
with a ~10% decline in the Nasdaq Biotechnology index .NBI
(Reporting by Raghav Mahobe)
((Raghav.Mahobe@thomsonreuters.com;))
Recent news on Spectrum Pharmaceuticals
See all newsBrief: Assertio Holdings Announces Favorable Vote On Proposed Acquisition Of Spectrum Pharmaceuticals
Brief: Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote “For” Proposed Deal With Assertio Holdings, Inc.
Brief: Spectrum Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
U.S. RESEARCH ROUNDUP-CTI Biopharma, Park National, Playags
Spectrum Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary